OncoMatch/Clinical Trials/NCT02945033
Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk
Is NCT02945033 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Molecular analysis of exon 9 and 20 of PI3K and blood intake for colorectal cancer.
Treatment: aspirin intake · Molecular analysis of exon 9 and 20 of PI3K · blood intake — Four retrospective studies were recently published on efficacy of aspirin in patients with surgically resected colon cancer. Two of these studies strongly suggested that aspirin used in low doses (100 mg/d) after surgical resection of colorectal cancer with PI3K mutation could act as a targeted therapy with a major protective effect on the risk of recurrence. The other two studies did not confirm the benefit of aspirin in this situation. These four retrospective studies provide an insufficient level of evidence to demonstrate the benefit of low-dose aspirin as adjuvant to surgery for colorectal cancer. Therefore, it is necessary as recommended in the conclusion of these studies and meta-analyses to perform a randomised prospective study to validate these data.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: PIK3CA mutation, exon 9 or 20
PI3K mutation, exon 9 or 20 (tumour)
Disease stage
Required: Stage III, II HIGH RISK
Colonic adenocarcinoma stage III; Colonic adenocarcinoma stage II high risk MSS: T4bN0 or T4aN0 tumour penetrating the surface of the visceral peritoneum or less than 12 nodes evaluated; or with at least two of the following criteria: lymphatic involvement, perineural invasion, venous invasion or diagnosis of bowel obstruction or perforation; or poor differentiated tumour.
Performance status
WHO 0–2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify